Characteristic | Healthy controls (n = 106) | Chronic Hepatitis B (n = 151) | HBV-ACLF (n = 160) | HBV-ACLF (n = 160) | ||
---|---|---|---|---|---|---|
Early stage (n = 32) | Middle stage (n = 61) | End stage (n = 67) | ||||
Age (years) | 43 (35–52) | 43 (35–51) | 45 (36–56) | 40 (32–56) | 49 (39–57) | 45 (37–53) |
BMI (kg/m2) | 23.3 (21.6–25.2) | 23.4 (21.8–26.6) | 24.0 (21.8–26.3) | 24.0 (21.3–26.5) | 23.9 (21.8–25.7) | 24.2 (21.6–26.4) |
Diabetes, % (n) | 7.5% (8) | 7.3% (11) | 8.1% (13) | 3.1% (1) | 11.5% (7) | 7.5% (5) |
Hypertension, % (n) | 17.0% (18) | 14.6% (22) | 18.1% (29) | 12.5% (4) | 23.0% (14) | 16.4% (11) |
ALT (U/L) | 15 (12–21) | 27 (19–35)a | 234 (116–442)b | 305 (182–466) | 158 (101–274)c | 269 (112–587)d |
AST (U/L) | 19 (16–22) | 24 (19–32)a | 129 (84–229)b | 158 (78–350) | 110 (75–147)c | 156 (92–280)d |
Albumin (g/dL) | 47 (45–49) | 48 (46–51) | 31 (29–34)b | 33 (31–36) | 31 (29–33)c | 31 (28–34) |
Tbil (μmol/L) | 11 (9–13) | 13 (10–18) | 350 (285–431)b | 304 (264–421) | 369 (290–420) | 370 (305–486) |
Platelet count (109/L) | 222 (192–264) | 193 (161–230) | 106 (71–138)b | 139 (108–193) | 100 (73–127)c | 98 (61–128) |
TT (ng/dL) | 567 (444–714) | 573 (444–743) | 101 (61–202)b | 291 (129–481) | 107 (59–187)c | 76 (45–130) |
SHBG (nmol/L) | 33 (27–47) | 37 (28–88) | 40 (28–55) | 55 (43–75) | 47 (31–57) | 32 (22–43)d |
FTI (%) | 57.3 (46.3–68.3) | 53 (41–64) | 9.7 (6.1–15.5)b | 17.6 (9.8–25.8) | 8.4 (6.4–11.9)c | 8.1 (5.4–13.7) |
DHEAS (μg/dL) | 304 (232–380) | 286 (183–364) | 152 (86–283)b | 183 (109–394) | 106 (48–200)c | 194 (97–292)d |
Cortisol (μg/dL) | 13.2 (9.3–16.0) | 11.7 (8.9–15.7) | 9.1 (6.9–12.5)b | 9.4 (7.5–14.8) | 8.8 (6.5–11.6) | 11.1 (5.5–15.0) |
Androstenedione (ng/mL) | 1.7 (1.3–2.3) | 1.8 (1.4–2.1) | 3.5 (2.3–4.7)b | 3.5 (2.9–4.8) | 2.8 (1.6–3.7) | 4.2 (2.6–5.6)d |